Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455090 | 0.87 | LTA4H (0.47) | LTA4HHTR2ADRD3JAK2SYK | |
| SCHEMBL31455642 | 0.84 | ALDH1A1 (0.50) | — | |
| SCHEMBL31455342 | 0.82 | ALDH1A1 (0.57) | — | |
| SCHEMBL31455394 | 0.81 | MAPT (0.36) | JAK2SYK | |
| SCHEMBL31455328 | 0.79 | DRD4 (0.44) | JAK2SYK | |
| SCHEMBL31455425 | 0.79 | GSK3B (0.36) | LTA4H | |
| SCHEMBL30802383 | 0.78 | SIGMAR1 (0.52) | DRD3 | |
| SCHEMBL27227252 | 0.78 | SIGMAR1 (0.52) | DRD3 | |
| SCHEMBL31455198 | 0.77 | SIGMAR1 (0.41) | JAK2SYK | |
| SCHEMBL27438740 | 0.75 | LTA4H (0.67) | LTA4HHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |